The state of Florida currently has 692 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
NCT05611931
Recruiting
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v 1.1\]) after completing at least 12 weeks of platinum-based therapy. A total of 220 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/20/2025
Locations: Broward Health Medical Center, Fort Lauderdale, Florida +3 locations
Conditions: Endometrial Cancer
Register for Updates
Exercise to ReGain Stamina and Energy (The EXERGISE Study)
NCT05684367
Recruiting
About 20%-70% of breast cancer survivors experience fatigue after cancer therapy. Because epidemiologic evidence shows that old age is a risk factor for fatigue in adults with cancer history, older breast cancer survivors suffer from even more fatigue than younger survivors. The purpose of this study is to test types of walking exercise interventions and their ability to reduce fatigue in older breast cancer survivors.
Gender:
FEMALE
Ages:
Between 60 years and 105 years
Trial Updated:
01/17/2025
Locations: Institute on Aging; University of Florida, Gainesville, Florida
Conditions: Fatigue, Breast Cancer, Cancer, Therapy-Related
Register for Updates
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
NCT04689048
Recruiting
The spread of cancer to the brain is referred to as brain metastases. Brain metastases are a common complication of cancer. This study is being done to determine whether the use of a new imaging agent, 18F-fluciclovine, is able to detect which patients are responding to radiation therapy. In addition, this study will look at the changes of the treated brain metastases using this imaging agent over time.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Miami Cancer Institute, Miami, Florida
Conditions: Brain Metastases, Adult, Brain Metastases, Brain Cancer
Register for Updates
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
NCT04829604
Recruiting
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Research Site, Hollywood, Florida +1 locations
Conditions: HER2 Positive Metastatic Breast Cancer
Register for Updates
Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma
NCT05561595
Recruiting
Stigma due to health conditions increases disease burden and adversely impacts health. The internalization of health-related stigma is associated with impaired mental health and quality of life. The current project will test the effects of a novel, transdiagnostic, group counseling intervention, and peer support, to determine the optimal method for helping patients cope with health-related stigma, reducing its internalization, and enhancing patient quality of life.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Obesity, Skin Disease, Cancer, HIV, Diabetes, Chronic Pain
Register for Updates
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
NCT05488548
Recruiting
A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/12/2025
Locations: Mayo Clinic Florida, Jacksonville, Florida
Conditions: Castrate Resistant Prostate Cancer, NUT Carcinoma, Chronic Myelomonocytic Leukemia, Myelofibrosis
Register for Updates
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
NCT04457596
Recruiting
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: AdventHealth Altamonte, Altamonte Springs, Florida +27 locations
Conditions: Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
Register for Updates
CtDNA Based MRD Testing for NAC Monitoring in TNBC
NCT06230185
Recruiting
A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC). Results from this study aim to improve MRD detection and disease outcomes for future patients.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/03/2025
Locations: Mount Sinai Medical Center of Florida, Miami Beach, Florida +1 locations
Conditions: TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease
Register for Updates
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
NCT06150664
Recruiting
This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/02/2025
Locations: D&H Cancer Research Center, Margate, Florida +2 locations
Conditions: Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma
Register for Updates
Modernizing Instructions to Improve Treatment Participation of Subjects During Their First Radiotherapy
NCT06246409
Recruiting
Daily patient participation is critical to the successful, life-saving delivery of radiotherapy. There is very little in the literature describing the best way to prepare patients to give optimal participation. This study aims to look at an already-prepared conversion of patient instruction materials and measure whether the improvement in clarity and specificity produces the desired changes in patient decision-making and emotional comfort.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
01/02/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Cancer
Register for Updates
Understanding of Genetics by Men At Risk for Prostate Cancer
NCT04550845
Recruiting
With this greater certainty regarding prognosis, men with localized prostate cancer are now equipped with make better treatment planning decisions. This study is designed to investigate the understanding of prognostic genetic technology in African American and rural White men at risk for localized prostate cancer.
Gender:
MALE
Ages:
Between 40 years and 95 years
Trial Updated:
12/24/2024
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Prostate Cancer
Register for Updates
A Phase 1/1b Study of IAM1363 in HER2 Cancers
NCT06253871
Recruiting
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/24/2024
Locations: Comprehensive Hematology Oncology, Saint Petersburg, Florida
Conditions: HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer, Brain Metastases from Solid Tumors, Brain Metastases from HER2 and Breast Cancer, CNS Metastases, HER2-Positive Solid Tumors, NSCLC (non-small Cell Lung Cancer), HER2-positive Bladder Cancer, HER2-positive Colorectal Cancer, HER2 + Gastric Cancer, HER2-positive Gastroesophageal Cancer
Register for Updates